REVVITY, INC. reported revenue of $0.73B for the period ended 2026-07-05, +1.3% year on year. Net income was $0.05B, a 7.1% net margin on a 57.1% gross margin. The largest revenue line is Diagnostics at 51% of the total. Free cash flow for the period was $0.28B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $0.73B | +1.3% |
| Gross profit | $0.42B | — |
| Operating income | $0.09B | — |
| Net income | $0.05B | -3.9% |
| Gross margin | 57.1% | Net margin 7.1% |
| Revenue Q/Q | +2.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| Diagnostics | $0.37B | 50.8% |
| Life Sciences | $0.36B | 49.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.31B | 42.9% |
| R&D | $0.05B | 6.7% |
| SG&A | $0.28B | 38.2% |
| Tax & other | $0.04B | 5.1% |
| Item | Amount |
|---|---|
| Total assets | $12.05B |
| Total liabilities | $4.82B |
| Shareholders' equity | $7.23B |
| Equity / assets | 60.0% |
| Operating cash flow | $0.31B |
| Capital expenditure | $0.03B |
| Free cash flow | $0.28B |
| Cash conversion (OCF / net income) | 370% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
HOOD ・ ROK ・ ROL ・ ROP ・ ROST ・ RCL ・ SPGI ・ CRM ・ SNDK ・ SBAC ・ SLB ・ STX
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies